BJC:食管鳞癌患者的多学科治疗策略研究

2016-11-13 MedSci MedSci原创

食管局部晚期鳞状细胞癌(SCC)的标准治疗是顺铂结合5-氟尿嘧啶(CF-RT)的放化疗。这个多中心II期临床试验的对象为最初不能手术切除的局部晚期食管SCC患者,评估多烯紫杉醇+顺铂、5 -氟尿嘧啶(DCF)诱导化疗(ICT)和随后转换手术(CS)的安全性与有效性。 研究纳入临床T4和/或不可切除的锁骨上淋巴结转移患者。开始治疗为三个周期的DCF-ICT,此后如果肿瘤可以切除,则进行CS;如

食管局部晚期鳞状细胞癌(SCC)的标准治疗是顺铂结合5-氟尿嘧啶(CF-RT)的放化疗。这个多中心II期临床试验的对象为最初不能手术切除的局部晚期食管SCC患者,评估多烯紫杉醇+顺铂、5 -氟尿嘧啶(DCF)诱导化疗(ICT)和随后转换手术(CS)的安全性与有效性。

研究纳入临床T4和/或不可切除的锁骨上淋巴结转移患者。开始治疗为三个周期的DCF-ICT,此后如果肿瘤可以切除,则进行CS;如果不能切除,则进行CF-RT,剂量为30–40 Gy,此后再次评估能否切除,如果能,则进行CS,如果不能,则完成60 Gy的CF-RT治疗。主要终点为1年总生存率(OS)。

共有48名患者参加研究,41.7%(n = 20)的患者进行了CS,包括DCF-CS (n=18)、DCF-CF-RT40Gy-CS (n=1)和DCF-CF-RT60Gy-CS (n=1)。19例(39.6%)为R0切除者。术后并发症等级大于或等于3的事件包括喉返神经麻痹、肺部感染、伤口感染、肺瘘、吞咽困难(各一例);没有发现CS患者出现严重术后并发症。4例(8.3%)患者CF-RT后出现临床完全缓解。估计1年OS为67.9%,80%置信区间的下限为59.7%。接受DCF-CF-RT60Gy治疗的患者中,发生了1例与治疗相关的死亡。

食管局部晚期鳞状细胞癌患者,对于DCF-ICT后CS这种多学科综合治疗策略,有良好的耐受性和疗效。

原始出处:


Tomoya Yokota1, Ken Kato2, Yasuo Hamamoto3, Yasuhiro Tsubosa.Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.British Journal of Cancer advance online publication 3 November 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822423, encodeId=c72c1822423a9, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed May 31 16:44:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156890, encodeId=bff11568906a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Nov 19 17:09:44 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437161, encodeId=9396143e1611d, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439820, encodeId=2f09143982047, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484629, encodeId=0d89148462918, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822423, encodeId=c72c1822423a9, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed May 31 16:44:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156890, encodeId=bff11568906a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Nov 19 17:09:44 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437161, encodeId=9396143e1611d, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439820, encodeId=2f09143982047, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484629, encodeId=0d89148462918, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=)]
    2016-11-19 李东泽

    很好,不错,以后会多学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1822423, encodeId=c72c1822423a9, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed May 31 16:44:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156890, encodeId=bff11568906a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Nov 19 17:09:44 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437161, encodeId=9396143e1611d, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439820, encodeId=2f09143982047, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484629, encodeId=0d89148462918, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=)]
    2016-11-15 zhouqu_8
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822423, encodeId=c72c1822423a9, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed May 31 16:44:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156890, encodeId=bff11568906a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Nov 19 17:09:44 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437161, encodeId=9396143e1611d, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439820, encodeId=2f09143982047, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484629, encodeId=0d89148462918, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822423, encodeId=c72c1822423a9, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed May 31 16:44:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156890, encodeId=bff11568906a, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Nov 19 17:09:44 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1437161, encodeId=9396143e1611d, content=<a href='/topic/show?id=0e311010591a' target=_blank style='color:#2F92EE;'>#食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101059, encryptionId=0e311010591a, topicName=食管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439820, encodeId=2f09143982047, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484629, encodeId=0d89148462918, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Tue Nov 15 04:44:00 CST 2016, time=2016-11-15, status=1, ipAttribution=)]

相关资讯

院士领衔扭转食管癌防治尴尬局面

我国是世界上食管癌发病率最高的国家之一。然而,上世纪90年代,我国食管癌患者的5年生存率仅为30.4%,远低于国际平均水平;到本世纪初,我国尚未建立高效、敏感的早期筛查技术,早诊早治目标人群也未确定;由于缺乏本土的规范化治疗指南,我国食管癌治疗策略只能照搬美国,治疗水平难以提高。 如今,食管癌防治的尴尬局面正在扭转。由中国科学院院士、中国医学科学院肿瘤医院院长赫捷领衔的研究团队,历时

盘点:近期食管鳞癌重要研究进展

鳞状细胞癌简称鳞癌,又名表皮癌,是发生于表皮或附属器细胞的一种恶性肿瘤,癌细胞有不同程度的角化。多见于有鳞状上皮覆盖的部位,如皮肤、口腔、唇、食管、子宫颈、阴道等处。此外,有些部位如支气管、膀胱、肾盂等处虽无鳞状上皮覆盖,但可通过鳞状上皮化生而形成鳞状细胞癌。本文梅斯医学小编为您盘点近期食管鳞癌重要研究进展。【1】ASTRO 2016:中国好声音——IV期食管鳞癌同步放化疗和单纯化疗的对比研究

ASCO 2014:局部进展期食管癌术前新辅助放化疗与单纯手术比较的III期试验

局部进展期食管鳞状细胞癌中术前新辅助放化疗与单纯手术比较的III期临床试验 摘要号:#Tps4146 第一作者:杨弘,中山大学附属肿瘤医院胸外科 背景:手术是食管鳞状细胞癌(ESCC)的主要治疗,不过局部进展期ESCC患者的预后相当差。术前放化疗后手术治疗似乎有望改善ESCC的生存。不过,不同研究的结果并不一致。我们进行了一项III期临床试验来评价多学科治疗对

病例:让人意外的直肠肿块

图1:内镜下所见直肠肿块 图2:内镜下窄带成像所见 近日意大利的胃肠病医生弗朗西斯·恩佐利在临床收治了这样一个病人,一位63岁老年女性因大便隐血阳性来做电子结肠镜检查,结果发现直肠有一稍平的结节隆起。该病例发表在最近的《Gut》上。 运用放大技术和窄带成像技术(NBI),初步诊断为侧向发育型肿瘤,镜下观察该肿块为结节混合型,最大直径30mm。黏膜pit分型为未

HPV与食管鳞癌相关新证据

   中美两国学者3月15日在线发表于《癌症流行病学、生物标志物和预防》(Cancer Epidemiology, Biomarkers & Prevention)杂志的一项流行病学研究表明,在中国食管鳞状细胞癌(ESCC)高发区,人乳头状瘤病毒(HPV)在其发病过程中发挥重要作用。   该研究在中国ESCC高发区河南安阳纳入了300例ESCC患者和与其年龄及性别相匹配的对照